64166
2-Hydroxyethyl methacrylate
puriss., ≥99.0% (GC)
Synonym(s):
1,2-Ethanediol mono(2-methylpropenoate), Glycol methacrylate, HEMA
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH2=C(CH3)COOCH2CH2OH
CAS Number:
Molecular Weight:
130.14
EC Number:
212-782-2
UNSPSC Code:
12162002
MDL number:
Beilstein/REAXYS Number:
1071583
vapor density
5 (vs air)
vapor pressure
0.01 mmHg ( 25 °C)
grade
puriss.
assay
≥99.0% (GC)
contains
~0.001% hydroquinone monomethyl ether as stabilizer
refractive index
n20/D 1.453
bp
67 °C/3.5 mmHg (lit.)
density
1.071 g/mL at 20 °C, 1.073 g/mL at 25 °C (lit.)
SMILES string
CC(=C)C(=O)OCCO
InChI
1S/C6H10O3/c1-5(2)6(8)9-4-3-7/h7H,1,3-4H2,2H3
InChI key
WOBHKFSMXKNTIM-UHFFFAOYSA-N
Still not finding the right product?
Explore all of our products under 2-Hydroxyethyl methacrylate
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
222.8 °F - closed cup
flash_point_c
106 °C - closed cup
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nina Yu Kostina et al.
Biomacromolecules, 13(12), 4164-4170 (2012-11-20)
Five poly(betaine) brushes were prepared, and their resistance to blood plasma fouling was studied. Two carboxybetaines monomers were copolymerized with 2-hydroxyethyl methacrylate (HEMA) to prepare novel hydrogels. By increasing the content of the zwitterionic comonomer, a 4-fold increase in the
Duncan Chege et al.
Journal of acquired immune deficiency syndromes (1999), 65(5), 517-525 (2013-11-22)
To evaluate if systemic murine malarial infection enhances HIV susceptibility through parasite-induced mucosal immune alterations at sites of HIV sexual exposure. Malaria and HIV have a high degree of geographical overlap and interact substantially within coinfected individuals. We used a
Brendan P Purcell et al.
Biomaterials, 33(31), 7849-7857 (2012-07-28)
Poor cell engraftment in the myocardium is a limiting factor towards the use of bone marrow derived cells (BMCs) to treat myocardial infarction (MI). In order to enhance the engraftment of circulating BMCs in the myocardium following MI, we have